Biotech has been on a tear over the past few years supported by a combination of scientific advances, great IPO and M&A exit environments, and robust capital markets for fundraising. Watching the public indices gives a good indicator of broader returns in the public equity ecosystem, but getting a handle on private venture capital returns is much harder.
